Meet Gentian and explore circulating calprotectin at CORA 2025

We are excited to announce that Gentian will be exhibiting at CORA 2025, the Congress on Controversies in Rheumatology & Autoimmunity, taking place on March 6–8, 2025, in Venice.

Join us at our booth to learn more about calprotectin’s potential as a biomarker in rheumatic diseases and how Gentian’s GCAL^® calprotectin assay is advancing diagnostics in this field.

Discover the power of circulating calprotectin

Calprotectin is gaining attention as a valuable inflammatory biomarker in rheumatology offering insights into disease activity:

• Calprotectin levels correlate with disease activity in inflammatory rheumatic diseases (IRDs) ^1-7
• Valuable tool to monitoring disease activity, treatment response and relapse ^8-10
• Risk marker for flares to guide treatment withdrawal ^11-15
• Differential diagnosis of Still’s disease in children with fever of unknown origin ¹⁶

Calprotectin testing is now recommended in EULAR, ACR, and PReS guidelines.

Explore GCAL®

The Gentian GCAL^® Calprotectin Immunoassay is a fast, reliable, and fully automated solution for measuring circulating calprotectin in plasma and serum. Designed for seamless integration, GCAL^® offers easy setup and broad compatibility with major clinical chemistry analysers, making it an efficient and scalable choice for both small and large laboratories.

Our team is ready to assist with your questions and validation setup for GCAL^®, ensuring seamless integration into your laboratory or the laboratory you use.

Meet our team and learn how to integrate circulating calprotectin into your clinical practice and laboratory

If you’re attending CORA 2025, don’t miss this opportunity to discover how Gentian’s GCAL^® assay can help improve patient management through sensitive and reliable inflammation detection that can enhance diagnostic output in rheumatology.

For more insights into calprotectin’s role in rheumatology, check out our latest articles:

• The Power of Calprotectin Testing in Rheumatology
• Circulating calprotectin in paediatrics: Benefits and clinical applications 
• Gentian GCAL® Calprotectin Immunoassay – about our assay 
  
  

We look forward to meeting you at #CORA2025.

Book a meeting – get in touch for more information

References:

1. Bae SC, Lee YH. Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis. Postgrad Med. 2017
2. Hammer HB et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis. 2007
3. Hurnakova J, et al. Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. PLoS One. 2017
4. Altobelli E et al. Serum Calprotectin a Potential Biomarker in Juvenile Idiopathic Arthritis: A Meta-Analysis. J Clin Med, 2021
5. Keskitalo PL et al. Myeloid-related protein 8/14 in plasma and serum in patients with new-onset juvenile idiopathic arthritis in real-world setting in a single center. Pediatr Rheumatol Online J, 2022
6. Guo Q et al. Serum calprotectin--a promising diagnostic marker for adult-onset Still's disease. Clin Rheumatol, 2016
7. La C et al. Serum calprotectin (S100A8/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis. RMD Open, 2021
8. Abildtrup M et al. Calprotectin as a biomarker for rheumatoid arthritis: a systematic review. J Rheumatol. 2015
9. Ramírez J et al. Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up. Semin Arthritis Rheum. 2017
10. Nielsen UB et al. Calprotectin in patients with chronic rheumatoid arthritis correlates with disease activity and responsiveness to methotrexate. Scand J Clin Lab Invest. 2018
11. Anink J et al. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Arthritis Res Ther, 2015
12. Alberdi-Saugstrup M et al. Low pretreatment levels of myeloid-related protein-8/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis. Clin Rheumatol, 2017
13. Schulze zur Wiesch A et al. Myeloid related proteins MRP8/MRP14 may predict disease flares in juvenile idiopathic arthritis. Clin Exp Rheumatol, 2004
14. Foell D et al. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? Ann Rheum Dis, 2004
15. Sumner EJ et al. Use of MRP8/14 in clinical practice as a predictor of outcome after methotrexate withdrawal in patients with juvenile idiopathic arthritis. Clin Rheumatol, 2022
16. Park C et al. MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever. Rheumatology (Oxford), 2021

This website may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances.